KR102848960B1 - 바이러스 및 박테리아 감염의 치료를 위한 신규한 mek-억제제 - Google Patents

바이러스 및 박테리아 감염의 치료를 위한 신규한 mek-억제제

Info

Publication number
KR102848960B1
KR102848960B1 KR1020207013451A KR20207013451A KR102848960B1 KR 102848960 B1 KR102848960 B1 KR 102848960B1 KR 1020207013451 A KR1020207013451 A KR 1020207013451A KR 20207013451 A KR20207013451 A KR 20207013451A KR 102848960 B1 KR102848960 B1 KR 102848960B1
Authority
KR
South Korea
Prior art keywords
bacterial
infection
virus
viral
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207013451A
Other languages
English (en)
Korean (ko)
Other versions
KR20200072499A (ko
Inventor
스테판 루드비히
올리버 플란츠
Original Assignee
아트리바 테라퓨틱스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아트리바 테라퓨틱스 게엠베하 filed Critical 아트리바 테라퓨틱스 게엠베하
Publication of KR20200072499A publication Critical patent/KR20200072499A/ko
Application granted granted Critical
Publication of KR102848960B1 publication Critical patent/KR102848960B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020207013451A 2017-10-17 2018-10-17 바이러스 및 박테리아 감염의 치료를 위한 신규한 mek-억제제 Active KR102848960B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LU100487 2017-10-17
LULU100487 2017-10-17
PCT/EP2018/078335 WO2019076947A1 (en) 2017-10-17 2018-10-17 NEW MEK INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS

Publications (2)

Publication Number Publication Date
KR20200072499A KR20200072499A (ko) 2020-06-22
KR102848960B1 true KR102848960B1 (ko) 2025-08-21

Family

ID=60484427

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207013451A Active KR102848960B1 (ko) 2017-10-17 2018-10-17 바이러스 및 박테리아 감염의 치료를 위한 신규한 mek-억제제

Country Status (21)

Country Link
US (2) US11903917B2 (enExample)
EP (2) EP3973960B1 (enExample)
JP (3) JP7227967B2 (enExample)
KR (1) KR102848960B1 (enExample)
CN (2) CN118141795A (enExample)
AU (2) AU2018351475A1 (enExample)
BR (1) BR112020007442A2 (enExample)
CA (1) CA3078424A1 (enExample)
CY (1) CY1124507T1 (enExample)
DK (1) DK3697405T3 (enExample)
EA (1) EA202090693A1 (enExample)
ES (2) ES2883639T3 (enExample)
HR (1) HRP20211252T1 (enExample)
HU (1) HUE055738T2 (enExample)
LT (1) LT3697405T (enExample)
MX (2) MX2020003473A (enExample)
PL (1) PL3697405T3 (enExample)
PT (1) PT3697405T (enExample)
SI (1) SI3697405T1 (enExample)
WO (1) WO2019076947A1 (enExample)
ZA (1) ZA202002069B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2883639T3 (es) * 2017-10-17 2021-12-09 Atriva Therapeutics Gmbh Nuevo inhibidor de MEK para el tratamiento de infecciones víricas y bacterianas
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
KR20220074869A (ko) 2019-08-27 2022-06-03 아트리바 테라퓨틱스 게엠베하 Mek 억제제와 캡-의존성 엔도뉴클레아제 억제제의 조합
KR20220079573A (ko) * 2019-10-08 2022-06-13 아트리바 테라퓨틱스 게엠베하 한타바이러스 감염의 치료를 위한 mek 억제제
ES2995196T3 (en) * 2020-05-20 2025-02-07 Atriva Therapeutics Gmbh Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm
CN112957361B (zh) * 2021-03-24 2022-07-29 中国科学院武汉病毒研究所 曲美替尼在制备抗沙粒病毒的抗病毒制剂中的应用
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170080045A1 (en) 2014-05-16 2017-03-23 Atriva Therapeutics Gmbh Novel-anti-infective strategy against influenza virus and s. aureus coinfections

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
EP1140067A1 (en) * 1999-01-07 2001-10-10 Warner-Lambert Company Antiviral method using mek inhibitors
AU5786000A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
DE10017480A1 (de) * 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
EP1467968A1 (en) 2002-01-23 2004-10-20 Warner-Lambert Company LLC N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
DE10300222A1 (de) * 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen
JP2007055983A (ja) * 2005-08-26 2007-03-08 Tokyo Univ Of Science 細胞内に侵入した病原性細菌に起因する疾患の予防・改善剤
US20150141380A1 (en) * 2010-08-05 2015-05-21 Case Western Reserve University Inhibitors of erk for developmental disorders of neuronal connectivity
EP2903649A1 (en) * 2012-10-08 2015-08-12 Westfälische Wilhelms-Universität Münster Mek inhibitors in the treatment of virus diseases
ES2883639T3 (es) 2017-10-17 2021-12-09 Atriva Therapeutics Gmbh Nuevo inhibidor de MEK para el tratamiento de infecciones víricas y bacterianas
KR20220079573A (ko) 2019-10-08 2022-06-13 아트리바 테라퓨틱스 게엠베하 한타바이러스 감염의 치료를 위한 mek 억제제
ES2995196T3 (en) 2020-05-20 2025-02-07 Atriva Therapeutics Gmbh Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170080045A1 (en) 2014-05-16 2017-03-23 Atriva Therapeutics Gmbh Novel-anti-infective strategy against influenza virus and s. aureus coinfections

Also Published As

Publication number Publication date
US20200289445A1 (en) 2020-09-17
CY1124507T1 (el) 2022-07-22
SI3697405T1 (sl) 2021-11-30
US20240245637A1 (en) 2024-07-25
MX2020003473A (es) 2020-10-01
HUE055738T2 (hu) 2021-12-28
HRP20211252T1 (hr) 2021-11-12
JP7618276B2 (ja) 2025-01-21
JP7227967B2 (ja) 2023-02-22
PL3697405T3 (pl) 2021-12-13
CN111479566B (zh) 2024-05-07
PT3697405T (pt) 2021-08-27
JP2023058631A (ja) 2023-04-25
EP3973960C0 (en) 2025-09-03
ES2883639T3 (es) 2021-12-09
EP3697405A1 (en) 2020-08-26
EP3973960B1 (en) 2025-09-03
JP2020537659A (ja) 2020-12-24
CN118141795A (zh) 2024-06-07
CA3078424A1 (en) 2019-04-25
AU2018351475A1 (en) 2020-04-30
DK3697405T3 (da) 2021-08-23
EP3697405B1 (en) 2021-07-14
ES3041322T3 (en) 2025-11-11
BR112020007442A2 (pt) 2020-10-27
US11903917B2 (en) 2024-02-20
ZA202002069B (en) 2021-10-27
LT3697405T (lt) 2021-10-25
KR20200072499A (ko) 2020-06-22
EP3973960A1 (en) 2022-03-30
JP2025031917A (ja) 2025-03-07
WO2019076947A1 (en) 2019-04-25
EA202090693A1 (ru) 2020-10-19
AU2024205853A1 (en) 2024-09-05
MX2022016066A (es) 2023-02-02
CN111479566A (zh) 2020-07-31

Similar Documents

Publication Publication Date Title
KR102848960B1 (ko) 바이러스 및 박테리아 감염의 치료를 위한 신규한 mek-억제제
US11135263B2 (en) Novel-anti-infective strategy against influenza virus and S. aureus coinfections
US12350244B2 (en) MEK-inhibitor for the treatment of viral and bacterial infections
EA042391B1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
HK40029715B (en) Novel mek-inhibitor for the treatment of viral and bacterial infections
HK40029715A (en) Novel mek-inhibitor for the treatment of viral and bacterial infections
AU2020258002B2 (en) Novel MEK-inhibitor for the treatment of viral and bacterial infections
EA047137B1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601